Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study was designed to compare the efficacy and safety of an oral dual tyrosine kinase
inhibitor in combination with capecitabine versus capecitabine alone in women with locally
advanced or metastatic breast cancer that has not responded to previous therapy.